NCT02210780View on ClinicalTrials.gov

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

PHASE2CompletedINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

August 5, 2014

Primary Completion Date

September 15, 2015

Study Completion Date

September 15, 2015

Conditions
Atopic Dermatitis
Interventions
DRUG

Dupilumab

Administered via subcutaneous injection.

DRUG

Placebo

An inactive substance containing no medicine administered via subcutaneous injection.

Trial Locations (42)

Unknown

Birmingham

Fort Smith

Long Beach

Los Angeles

Mission Viejo

Rolling Hills Estates

San Diego

Santa Monica

Denver

Jacksonville

Miami

Tampa

Macon

Chicago

Maywood

West Dundee

Indianapolis

Plainfield

Overland Park

Boston

Ann Arbor

Troy

St Louis

Hackensack

Albuquerque

Buffalo

Forest Hills

New York

Cleveland

Norman

Tulsa

Medford

Portland

Pittsburgh

Charleston

Greer

Arlington

Austin

Houston

Webster

Richmond

Seattle

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02210780 - Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD) | Biotech Hunter | Biotech Hunter